Evidence map›Paper›PMID 30429882›Full record

ArticleTheranostics2018

Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling.

Zhi Huang, Wei Zhou, Yongtao Li, Mei Cao, Tianqi Wang, Yakun Ma, Qingxiang Guo, Xin Wang, Chao Zhang, Chenglan Zhang and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Zhi HuangDepartment of Medicinal Chemistry, School of Medicine, Nankai University, Tianjin 300071, China.
Wei ZhouDepartment of Medicinal Chemistry, School of Medicine, Nankai University, Tianjin 300071, China.
Yongtao LiDepartment of Medicinal Chemistry, School of Medicine, Nankai University, Tianjin 300071, China.
Mei CaoDepartment of Medicinal Chemistry, School of Medicine, Nankai University, Tianjin 300071, China.
Tianqi WangDepartment of Medicinal Chemistry, School of Medicine, Nankai University, Tianjin 300071, China.
Yakun MaDepartment of Medicinal Chemistry, School of Medicine, Nankai University, Tianjin 300071, China.
Qingxiang GuoDepartment of Medicinal Chemistry, School of Medicine, Nankai University, Tianjin 300071, China.
Xin WangDepartment of Medicinal Chemistry, School of Medicine, Nankai University, Tianjin 300071, China.
Chao ZhangDepartment of Medicinal Chemistry, School of Medicine, Nankai University, Tianjin 300071, China.
Chenglan ZhangDepartment of Medicinal Chemistry, School of Medicine, Nankai University, Tianjin 300071, China.
Wenzhi ShenDepartment of Pathology and Institute of Precision Medicine, Jining Medical University, Jining 272067, China.
Yanhua LiuState Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin 300071, China.
Yanan ChenState Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin 300071, China.
Jianyu ZhengState Key Laboratory and Institute of Elemento-Organic Chemistry, Collaborative Innovation Center of Chemical Science and Engineering, Nankai University, Tianjin 300071, China.
Shengyong YangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Collaborative Innovation Center for Biotherapy and Sichuan University, Chengdu 610041, China.
Yan FanDepartment of Medicinal Chemistry, School of Medicine, Nankai University, Tianjin 300071, China.
Rong XiangDepartment of Medicinal Chemistry, School of Medicine, Nankai University, Tianjin 300071, China.
Nankai University · CNJining Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite initial progress in preclinical models, most known histone deacetylase inhibitors (HDACis) used as a single agent have failed to show clinical benefits in nearly all types of solid tumours. Hence, the efficacy of HDACis in solid tumours remains uncertain. Herein, we developed a hybrid HDAC inhibitor that sensitized solid tumours to HDAC-targeted treatment.

Indexed as

AnimalsAntineoplastic AgentsApoptosisBreast NeoplasmsCell CycleCell ProliferationDisease Models, AnimalFemaleGene Expression ProfilingHistone Deacetylase InhibitorsJanus Kinase 1MiceModels, TheoreticalOvarian NeoplasmsProto-Oncogene Proteins c-bcl-2Signal TransductionAntineoplastic AgentsBcl2 protein, mouseHistone Deacetylase InhibitorsJak1 protein, mouseJanus Kinase 1Proto-Oncogene Proteins c-bcl-2Stat3 protein, mouseSTAT3 Transcription FactorCDK4/6HDAC1inhibitorJAK1solid tumour

Identifiers

PMID30429882
PMCPMC6217055
OpenAlexW2898420718

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.